GPM Reminds Investors of the January 5 Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Limited
03 Janvier 2017 - 9:44PM
Business Wire
Investors with over $100,000 in losses are encouraged to contact
Lesley Portnoy, Esquire to discuss their legal rights.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the
January 5, 2017 deadline to file a lead plaintiff motion in
the class action filed on behalf of a class (the “Class”) of
investors who purchased Teva Pharmaceutical Industries Limited
(“Teva” or the “Company”) (NYSE: TEVA) securities between
February 10, 2014 and November 3, 2016, inclusive (the
“Class Period”).
On November 3, 2016, Bloomberg published the article “U.S.
Charges in Generic-Drug Probe to Be Filed by Year End” which
discussed the Department of Justice's two year investigation of
suspected price collusion by several pharmaceutical companies,
including Teva, which will likely result in prosecutors filing
criminal charges by the end of the year.
The complaint filed in this lawsuit alleges that Defendants made
false and/or misleading statements and/or failed to disclose that:
(1) Teva and several of its pharmaceutical industry peers colluded
to fix generic drug prices; (2) the foregoing conduct constituted a
violation of federal antitrust laws; (3) consequently, Teva’s
revenues during the Class Period were in part the result of illegal
conduct; and (4) as a result, Teva’s public statements were
materially false and misleading at all relevant times.
If you purchased Teva shares, you may move the Court no later
than January 5, 2017 to request appointment as
lead plaintiff. To be a member of the class you need not take any
action at this time; you may retain counsel of your choice or take
no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170103006258/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024